AddLife AB Class B
181.00
SEK
-5.10
(-2.74%)
ISIN
SE0014401378
Return %
Stock
S&P 500
1Y
-2.42
14.20
3Y
211.98
81.12
5Y
-47.63
68.34
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Quarterly Revenue
SEK
•
in mil. unless spec.Quarterly Earnings Per Share
SEK
•
in mil. unless spec.Quarterly Dividends Per Share
SEK
•
in mil. unless spec.Company Description
- CEO
- Fredrik Dalborg
- Full Time Employees
- 2,295
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- Brunkebergstorg 5 Stockholm AB Sweden 103 62
- IPO Date
- Mar 15, 2016
- Website
- add.life
- Similar Companies
- Business
- AddLife AB (publ) is a Swedish medical technology company primarily engaged in the healthcare sector, offering a broad range of products and services through two main business segments: Labtech and Medtech. The Labtech segment supplies laboratory equipment, analytical instruments, reagents, and consumables used in diagnostics, biomedical research, and pharmaceutical development. The Medtech segment provides medical devices, consumables, instruments, assistive equipment, and digital solutions primarily targeted at hospitals, publicly funded healthcare, home care, and social care across Europe. AddLife operates approximately 85 subsidiaries with a workforce of around 2,300 employees, serving customers mainly in the Nordic region and broader European markets. The company was founded in 2016 and is headquartered in Stockholm, Sweden. The company’s product portfolio includes in-house manufactured products as well as third-party offerings, covering areas such as diagnostics, laboratory analysis, medical devices, surgical instruments, and digital healthcare solutions. The Medtech segment is structured into Hospital and Homecare units, with a focus on continuously developing product portfolios and strengthening market positions. AddLife places strong emphasis on customer support, reliable deliveries, and service offerings including advisory, education, and maintenance. Recent significant changes include the acquisition of BonsaiLab in 2024, a leading Spanish distributor in cell and molecular biology, adding approximately SEK 90 million in annual sales and expanding AddLife’s presence in the Spanish and Portuguese markets. Additionally, the company announced a strategic collaboration with MGI Tech Co., Ltd. to expand distribution of MGI's products in the Nordic region. AddLife has also been engaged in operational restructuring in its ophthalmic surgery business, improving margins through cost reductions and a refocus on sales growth. The group closed its Camanio homecare business in late 2024 for cost efficiency. Overall, AddLife continues to invest in expanding its product portfolio and digital capabilities, including a new digital platform initiative for enhanced customer interaction planned for 2025. AddLife’s operations span about 30 countries in Europe with notable market presence in Sweden, Norway, Denmark, Finland, Germany, Spain, Italy, Switzerland, the UK, Ireland, and other regions. The company targets healthcare providers, research institutions, pharmaceutical companies, and public healthcare systems. Its growth strategy is driven by acquisitions and integrating niche market companies focused on high-quality and specialized medical and laboratory technology solutions. In summary, AddLife AB is a Swedish public medical technology company offering comprehensive medical, laboratory, and digital healthcare products and services primarily across Europe, with recent strategic acquisitions and collaborations enhancing its footprint and product portfolio, backed by around 85 subsidiaries and 2,300 employees headquartered in Stockholm. This positions AddLife as a dynamic player in the Medtech and Labtech sectors, continuously evolving through acquisitions and innovation.